Celltrion Moves to Expand Zymfentra Use in the U.S. With New Phase 4 Trial

Celltrion is intensifying efforts to broaden the use of Zymfentra in the United States through a new Phase 4 trial. The South Korean company submitted an Investigational New Drug (IND) application to the FDA for a study examining a 240mg dose of Zymfentra, a subcutaneous formulation, compared to high-dose intravenous infliximab.

The trial will involve 447 patients with Crohn's disease or ulcerative colitis across 55 U.S. medical centers, focusing on establishing clinical evidence for non-inferiority of the higher dose. If successful, Zymfentra could offer U.S. physicians a two-dose treatment approach, complementing the existing 120mg regimen. This strategy echoes Celltrion's approach with Remsima SC in Europe, which recorded a 32% market share in the first quarter of the year.

Expanding dosing options is part of Celltrion's broader growth strategy, including pursuing additional clinical development for rheumatoid arthritis (RA) to widen Zymfentra's potential patient base. Zymfentra has already seen strong commercial growth in the U.S., generating 99.5 billion won ($72 million) in sales during the first half of the year and securing reimbursement coverage for over 90% of insured patients.

Industry analysts suggest that factors beyond clinical efficacy, such as reimbursement access, prescribing convenience, and differentiated dosing options, are increasingly influencing a product's market penetration in the U.S. biologics market. Celltrion aims to leverage these expanded dosing options, potential new indications, and its direct-sales infrastructure to enhance Zymfentra's position in the American autoimmune disease market.